ArriVent BioPharma, Inc. — Insider Transactions
Form 4 filings by directors, officers, and 10%+ shareholders
SEC rules require corporate insiders — including directors, executive officers, and any shareholder owning more than 10% of a company's shares — to report changes in their ownership within two business days of a transaction. These disclosures are filed as Form 4. Open-market purchases (code P) are generally considered the most meaningful signal, as insiders are spending their own money.
| Insider | Title | Type | Shares | Price | Value | Owns After | Date |
|---|---|---|---|---|---|---|---|
| LaChapelle Robin | Chief Operating Officer | Option Exercise | 2,600 | $2.28 | $5,928 | 129,233 | Jul 11, 2025 |
| LaChapelle Robin | Chief Operating Officer | Option Exercise | 2,867 | $2.28 | $6,537 | 102,584 | Sep 19, 2024 |
| HHLR ADVISORS, LTD. | — | C | 3,616,041 | — | — | 3,616,041 | Jan 30, 2024 |
| OrbiMed Asia GP IV, L.P. | — | C | 821,827 | — | — | 821,827 | Jan 30, 2024 |
| GORDON CARL L | — | Purchase | 222,222 | $18.00 | $3,999,996 | 1,513,664 | Jan 30, 2024 |
| HEALY JAMES | — | Purchase | 444,444 | $18.00 | $7,999,992 | 1,696,752 | Jan 30, 2024 |